scholarly journals Synchronous Primary Endometrial Carcinoma and Metastatic Malignant Melanoma in Cervical Lymph Node

2017 ◽  
Author(s):  
Kanwardeep Tiwana
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Endometrial Carcinoma ◽  
Cervical Lymph Node ◽  
Metastatic Malignant Melanoma

Rate of false-negative findings in sentinel lymph node biopsy in patients with head and neck malignant melanoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17566-e17566
Author(s):  
Roman Rahimi-Nedjat ◽  
Keyvan Sagheb ◽  
Maike Hormes ◽  
Andrea Tuettenberg ◽  
Bilal Al-Nawas ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Malignant Melanoma ◽  
Cervical Lymph Node ◽  
False Negative ◽  
Lymph Node Biopsy ◽  
Tumor Thickness ◽  
Node Biopsy ◽  
Negative Findings ◽  
One Year

e17566 Background: Sentinel Lymph Node Biopsy (SLNB) is the standard procedure for malignant melanoma with a thicknes above 1mm. However, the benefits of this procedure have recently been questioned because of a high number of false negative findings. The aim of our study was to investigate the number of early recurrence in patients with negative SLNB. Methods: All patients with malignant melanoma of the head and neck region who underwent SLNB between 2010 and 2016 in our department were included and data reviewed retrospectively. Recurrence in the same cervical lymph node region of the previously extirpated sentinel lymph node (SLN) within one year was defined as primary false-negative. Results: Allover 101 patients were investigated (mean age 62.48 years (±17.66; 73.3% ♂, 26.7% ♀). Most frequent location of the primary melanoma were the cheeks and ears (each 18.8%), followed by the hair bearing region (13.9%). Superficial Spreading Melanoma and Nodular Melanoma were the most frequently seen subtypes (each 23.8%), followed by Lentigo maligna Melanoma (19.8%). Median thickness of all patients was 2.5mm (min: 0.15 – max: 10.0 mm). In average 3 SLN were removed during operation (min: 1 – max 16). In 79.2% of the cases the SLN was negative. 13% showed one metastasis, 5.2% showed two and 1.6% three metastases. Positive findings in the SLN were significantly correlated with T-classification. Ulceration and tumor thickness showed significant tendencies in Χ2-Test and Mann-Whitney-Test. Out of the patients with negative SLN 13.1% had at least one metastasis in a cervical lymph node of the same region within one year. Mean duration until recurrence was 6.5 months. 75.0% of the metastases in our study were diagnosed within this period. 62.5% of the patients with secondary positive SLN had a tumor of intermediate thickness (between 1mm and 4mm). Conclusions: With 13.1 % secondary positive SLN this study shows that SLNB has a high rate of false-negative findings. However, SLNB has lower complication rates compared to traditional lymph node extirpation. This study shows that patients with negative SLN especially with intermediate tumor thickness should be controlled by ultrasound or computer tomography in short intervals.

Anthracofibrotic Lymph Node of Neck Mimicking Metastatic Malignant Melanoma in a Patient With Gastric Cancer

2019 ◽  
Vol 27 (7) ◽  
pp. 778-780
Author(s):  
Dong Hoon Lee ◽  
Jo Heon Kim ◽  
Sang Hee Cho ◽  
Tae Mi Yoon ◽  
Joon Kyoo Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Malignant Melanoma ◽  
Unusual Case ◽  
Neck Region ◽  
Metastatic Malignant Melanoma ◽  
Rare Occurrence ◽  
Cancer History ◽  
Head And Neck Region ◽  
Appropriate Treatment

Extrathoracic anthracofibrosis in head and neck region is of extremely rare occurrence and can be confused with malignancy. In this article, we report an unusual case of an anthracofibrotic lymph node of neck that was mistaken for metastatic malignant melanoma in a gastric cancer patient. Because the incidence of an anthracofibrotic lymph node of the neck is very low, it is important to distinguish it from other diseases, including malignancy or metastasis, especially in patients with a cancer history. Thus, pathological diagnosis of anthracofibrosis is necessary to make an accurate diagnosis and find appropriate treatment.

Metastatic Malignant Melanoma of the Inguinal Lymph Node with Unknown Primary Lesion: A Case Report

2017 ◽  
Vol 3 (2) ◽  
pp. 13
Author(s):  
Guddi Rani Singh ◽  
Jiut Ram Keshari ◽  
Bhim Ram ◽  
Vijayanand choudhary ◽  
Ravi Bhushan Raman
Keyword(s):  
Case Report ◽  
Lymph Node ◽  
Malignant Melanoma ◽  
Inguinal Lymph Node ◽  
Metastatic Malignant Melanoma ◽  
Primary Lesion ◽  
Unknown Primary

Metastatic Malignant Melanoma Involving the Parotid Lymph Node Region: A Clinicopathologic Report of 5 Cases

2008 ◽  
Vol 66 (4) ◽  
pp. 809-813 ◽  
Author(s):  
Menachem Gross ◽  
Bella Maly ◽  
Alexander Maly ◽  
Michal Lotem ◽  
Ron Eliashar
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Metastatic Malignant Melanoma

scholarly journals Metastatic Malignant Melanoma of the Inguinal Lymph Node with Unknown Primary Lesion

2015 ◽  
Vol 2015 ◽  
pp. 1-4 ◽  
Author(s):  
Sherif Ali Eltawansy ◽  
Ryane Panasiti ◽  
Samaa Hasanien ◽  
Dennis Lourdusamy ◽  
David Sharon
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Spontaneous Regression ◽  
Inguinal Lymph Node ◽  
Cutaneous Lesion ◽  
Metastatic Malignant Melanoma ◽  
Primary Lesion ◽  
Primary Site ◽  
Unknown Primary ◽  
Cutaneous Lesions

Background. Malignant melanoma could present with metastasis with unknown primary (MUP) and this happens in 2-3% according to the studies. Around 90% of melanomas have cutaneous origin, but still there are melanomas that could be found in visceral organs or lymph nodes with unknown primary site. Spontaneous regression of the primary site could be an explanation.Case Report. We report a 58-year-old Caucasian male who presented with a right sided swelling in the inguinal region. Surgery was performed and biopsy showed metastatic malignant melanoma. No cutaneous lesions were identified by history or physical examination. Work up could not detect the primary lesion and patient was started on radiotherapy and immunotherapy.Conclusion. We present a case of malignant melanoma of unknown primary presenting in an unusual place which is the inguinal lymph node. Theories try to explain the pathway of development of such tumors and one of the theories mentions that it could be a spontaneous regression of the primary cutaneous lesion. Another theory is that it could be from transformation of aberrant melanocyte within the lymph node. Prognosis is postulated to be better in this case than in melanoma with a known primary.

Soluble VEGF-A and lymphangiogenesis in metastatic malignant melanoma patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8049-8049 ◽  
Author(s):  
C. Soubrane ◽  
R. Mouawad ◽  
V. Sultan ◽  
J. Spano ◽  
D. Khayat ◽  
...  
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Lymph Node Metastasis ◽  
Metastatic Malignant Melanoma ◽  
Tumor Burden ◽  
Node Metastasis ◽  
Healthy Donors ◽  
Wide Range ◽  
Melanoma Patients ◽  
Metastatic Sites

8049 Background: Vascular endothelial growth factor (VEGF-A) and its circulating form (sVEGF-A) play a major role in tumor progression and angiogenesis. However, the clinical implications of circulating VEGF-A in metastatic malignant melanoma patients and its role in tumor-associated lymphangiogenesis and lymphatic metastasis remained unclear. Objectives: The aim of this study is to evaluate the potential role of circulating VEGF-A levels in lymphangiogenesis and its usefulness in metastatic malignant melanoma patients. Methods and Patients: using a sensitive enzyme-linked immunosorbent assays, VEGF-A level was measured in sera of 65 patients treated by biochemotherapy with a fully documented history of disease in comparison with 30 healthy controls. Results: A wide range (0- 566 pg/ml) of pretreatment sVEGF-A level was detected in the serum of MMM patients and the median level (40.5 pg/ml) was significantly higher (p=0.0007) than that of healthy donors (7.5 pg/ml). Age, gender and LDH were not associated with sVEGF-A levels. Regarding tumor burden, median pretreatment sVEGF-A level was higher in patients with high tumor burden (n= 40) as compared to patients with low tumor burden (n=25). Furthermore, the most surprising finding of our study was that patients with only lymph node metastasis (n=23) had a significantly (p= 0.021) higher median sVEGF-A levels (45.7 pg/ml) as compared to the 42 patients with different metastatic sites (16.6 pg/ml). Conclusion: these results suggest that sVEGF-A levels may predict lymph node metastasis in metastatic malignant melanoma patients. In addition, it may be promising targets for new therapeutic strategies in melanoma disease. No significant financial relationships to disclose.

Isolated Metastatic Malignant Melanoma of the Right Inguinal Lymph Node with Unknown Primary Lesion

2018 ◽  
Vol 8 (3) ◽  
pp. 174-176
Author(s):  
Debasish Das ◽  
Deb Prosad Paul ◽  
Kazi Sohel Iqbal
Keyword(s):  
Lymph Node ◽  
Malignant Melanoma ◽  
Inguinal Lymph Node ◽  
Uv Light ◽  
Light Exposure ◽  
Metastatic Malignant Melanoma ◽  
Lymph Node Biopsy ◽  
Primary Lesion ◽  
Unknown Primary ◽  
Complete Excision

Malignant melanoma develops from the pigment containing cells known as melanocytes. Melanoma is more common in men than in women. It is found typically in the skin. It is also found in the mouth, intestine, eye and other sites. Melanoma may develop from a mole with changes including an increasing in size, irregular edges, changes in color, itchiness or skin breakdown. Prognosis is poor if it is not treated early. The primary cause of melanoma is UV light exposure. Patients with history of affected family members and poor immune function are at greater risk. Diagnosis is by biopsy from any affected skin lesion. Recurrence is common even many years after the initial diagnosis. Here we present a case of malignant melanoma of the inguinal lymph node with unknown primary lesion. Surgery was done with complete excision of inguinal lymph node. Biopsy report showed metastatic malignant melanoma.J Enam Med Col 2018; 8(3): 174-176

Sign in / Sign up

Export Citation Format

Share Document